Heron Therapeutics Inc. (HRTX)
| Bid | 2.26 |
| Market Cap | 350.36M |
| Revenue (ttm) | 153.74M |
| Net Income (ttm) | -13.58M |
| EPS (ttm) | -0.09 |
| PE Ratio (ttm) | -25.56 |
| Forward PE | 48.6 |
| Analyst | Buy |
| Ask | 2.35 |
| Volume | 1,328,090 |
| Avg. Volume (20D) | 1,646,258 |
| Open | 2.38 |
| Previous Close | 2.35 |
| Day's Range | 2.29 - 2.42 |
| 52-Week Range | 1.04 - 3.93 |
| Beta | 1.40 |
About HRTX
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acut...
Analyst Forecast
According to 2 analyst ratings, the average rating for HRTX stock is "Buy." The 12-month stock price forecast is $5.5, which is an increase of 139.13% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
Heron Therapeutics, Inc. (HRTX) Q4 2024 Earnings Call TranscriptHeron Therapeutics, Inc. (NASDAQ:HRTX ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Melissa Jarel - Executive Director, Legal Craig Collard - Chief Executive Off...
